Several analysts have recently updated their ratings and price targets for GlaxoSmithKline PLC (NYSE: GSK):

  • 9/20/2016 – GlaxoSmithKline PLC had its “buy” rating reaffirmed by analysts at Bank of America Corp.. They now have a $50.00 price target on the stock.
  • 9/16/2016 – GlaxoSmithKline PLC had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 9/16/2016 – GlaxoSmithKline PLC had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • 9/14/2016 – GlaxoSmithKline PLC had its “buy” rating reaffirmed by analysts at Jefferies Group.
  • 9/13/2016 – GlaxoSmithKline PLC was downgraded by analysts at BNP Paribas from a “neutral” rating to an “underperform” rating.
  • 9/12/2016 – GlaxoSmithKline PLC had its “buy” rating reaffirmed by analysts at HSBC.
  • 8/17/2016 – GlaxoSmithKline PLC had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/12/2016 – GlaxoSmithKline PLC had its price target raised by analysts at Argus from $48.00 to $50.00. They now have a “buy” rating on the stock.
  • 8/11/2016 – GlaxoSmithKline PLC had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/10/2016 – GlaxoSmithKline PLC had its “buy” rating reaffirmed by analysts at Citigroup Inc..
  • 8/2/2016 – GlaxoSmithKline PLC had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • 7/31/2016 – GlaxoSmithKline PLC had its “neutral” rating reaffirmed by analysts at BNP Paribas.
  • 7/28/2016 – GlaxoSmithKline PLC had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc..
  • 7/27/2016 – GlaxoSmithKline PLC had its “buy” rating reaffirmed by analysts at Citigroup Inc..
  • 7/27/2016 – GlaxoSmithKline PLC had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/25/2016 – GlaxoSmithKline PLC had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/25/2016 – GlaxoSmithKline PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Glaxo, focused on three core businesses – Pharmaceuticals, Vaccines and Consumer Healthcare – is positioned to deliver double-digit core earnings growth from 2016. The company’s diversified base and presence in different geographical areas should help support revenues. We are positive on the performance of new products as well as those acquired from Novartis. These should help support revenues and ease the impact of the loss of Advair sales. We are also positive on Glaxo’s efforts in developing its pipeline candidates. Moreover, Glaxo’s efforts to increase cost efficiency and its outlook for the next five years bode well. However, challenges remain in the form of increasing competition, genericization and pricing pressure, which will continue to impact the company’s performance. In particular, pricing dynamics and competitive pressure are expected to continue hurting Advair’s performance.”

GlaxoSmithKline PLC (NYSE:GSK) traded down 0.86% on Wednesday, hitting $42.69. 1,634,979 shares of the stock were exchanged. The company has a 50-day moving average price of $43.91 and a 200 day moving average price of $42.60. GlaxoSmithKline PLC has a 1-year low of $37.24 and a 1-year high of $45.58. The company has a market capitalization of $103.76 billion, a PE ratio of 2668.12 and a beta of 0.85.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/analysts-weekly-ratings-updates-for-glaxosmithkline-plc-gsk.html

The company also recently declared a dividend, which will be paid on Thursday, October 13th. Investors of record on Friday, August 12th will be given a dividend of $0.494 per share. The ex-dividend date of this dividend is Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio is 6,600.00%.

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.